GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » Equity-to-Asset

ProtoKinetix (ProtoKinetix) Equity-to-Asset : 0.86 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ProtoKinetix's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $0.39 Mil. ProtoKinetix's Total Assets for the quarter that ended in Mar. 2024 was $0.46 Mil.

The historical rank and industry rank for ProtoKinetix's Equity-to-Asset or its related term are showing as below:

PKTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -71.33   Med: 0.91   Max: 0.99
Current: 0.86

During the past 13 years, the highest Equity to Asset Ratio of ProtoKinetix was 0.99. The lowest was -71.33. And the median was 0.91.

PKTX's Equity-to-Asset is ranked better than
77.51% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs PKTX: 0.86

ProtoKinetix Equity-to-Asset Historical Data

The historical data trend for ProtoKinetix's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix Equity-to-Asset Chart

ProtoKinetix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 0.90 0.79 0.91 0.91

ProtoKinetix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.97 0.97 0.91 0.86

Competitive Comparison of ProtoKinetix's Equity-to-Asset

For the Biotechnology subindustry, ProtoKinetix's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProtoKinetix's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProtoKinetix's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where ProtoKinetix's Equity-to-Asset falls into.



ProtoKinetix Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

ProtoKinetix's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=0.436/0.481
=

ProtoKinetix's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=0.394/0.461
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProtoKinetix  (OTCPK:PKTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


ProtoKinetix Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ProtoKinetix (ProtoKinetix) Business Description

Traded in Other Exchanges
N/A
Address
412 Mulberry Street, Marietta, OH, USA, 45750
ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.
Executives
Clarence Edward Smith director, 10 percent owner, officer: President & CEO 1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta officer: CFO 412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young 10 percent owner 6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough director 1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward officer: CFO 705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen director 4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory director 2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior director, officer: CEO PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum director, officer: President C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix (ProtoKinetix) Headlines